Clinical Trials Logo

Cholestasis clinical trials

View clinical trials related to Cholestasis.

Filter by:

NCT ID: NCT02582541 Recruiting - Cholangiocarcinoma Clinical Trials

Endoscopic Biliary RFA of Malignant Bile Duct Obstruction

Start date: February 2014
Phase: N/A
Study type: Interventional

Endoscopic radiofrequency ablation (RFA) is a new palliation therapy for malignant bile duct obstruction. It delivers a high amount of thermal energy to target tissue and may prolong the duration of stent patency. RFA has showed promising results for malignant bile duct obstruction and increasing the duration of stent patency. The aim of our study was to evaluate the feasibility and safety of endoscopic RFA for the treatment of bile duct obstructions, and to compare the efficacy of Endoscopic biliary RFA with the addition of self-expanding metal stents (SEMS) to SEMS alone in a randomized controlled trial.

NCT ID: NCT02480478 Recruiting - Clinical trials for Intrahepatic Cholestasis of Pregnancy

Serum Autotaxin Levels in Cholestasis of Pregnancy

Start date: June 2015
Phase: N/A
Study type: Observational

Intrahepatic cholestasis of pregnancy is the most common liver disease in pregnancy. It is is a pregnancy-specific liver disorder with onset mainly in the third trimester of pregnancy. ICP is characterized by pruritus, elevated serum fasting bile salts and transaminases and an increased risk of adverse fetal outcomes. Serum autotaxin levels were found highly sensitive and specific biomarker to to differentiate ICP from other pregnancy-related liver disorders or pruritic dermatoses. The purpose of the study is to determine the diagnostic accuracy of serum autotaxin activity in cholestasis of pregnancy.

NCT ID: NCT02334293 Recruiting - Cholestasis Clinical Trials

Omegaven® as Parenteral Nutrition

Start date: October 2013
Phase: N/A
Study type: Interventional

The purpose of this study is to determine if a fat emulsion comprised of omega-3 fatty acids, Omegaven, would be beneficial in the management of steatotic liver injury in parenteral nutrition (PN) by its inhibition of de novo lipogenesis, the reduction of arachidonic acid-derived inflammatory mediators, prevention of essential fatty acid deficiency through the presence of small amounts of arachidonic acid, and improved clearance of lipids from the serum.

NCT ID: NCT02192177 Recruiting - Pregnancy Clinical Trials

Apoptosis May Have a Role in Etiopathogenesis of Obstetric Cholestasis.

Start date: September 2013
Phase: N/A
Study type: Observational

Intrahepatic cholestasis of pregnancy is a disease specific to pregnancy period; especially late second and third trimester. We aimed to investigate the role of apoptosis in etiopathogenesis of obstetric cholestasis.

NCT ID: NCT02024295 Recruiting - Clinical trials for Hepatitis, Alcoholic

Efficacy and Safety of S-adenosyl-l-methionine in Treatment of Alcoholic Hepatitis With Cholestasis

Start date: December 2013
Phase: Phase 4
Study type: Interventional

To determine the efficacy and safety S-adenosyl-l-methionine in alcoholic hepatitis with cholestasis.

NCT ID: NCT01998620 Recruiting - Hepatitis B Clinical Trials

Efficacy and Safety of S-adenosyl-L-methionine in Treatment of Chronic Hepatitis B Patients With Cholestasis

Start date: November 2013
Phase: Phase 4
Study type: Interventional

This is an evaluation of adenosine methionine for treatment of chronic hepatitis b patients with cholestasis efficacy and safety of multicenter, randomized, open label clinical trial.

NCT ID: NCT01958216 Recruiting - Clinical trials for Occlusion of Bile Duct With an External Bile Diversion.

in Vivo TICE (TransIntestinal Cholesterol Excretion)

in vivoTICE
Start date: September 2013
Phase: N/A
Study type: Interventional

So far, the liver has been the main target for cholesterol elimination. However, several recent studies performed in mice have described a new route of cholesterol excretion, the Trans-Intestinal Cholesterol Excretion or TICE. TICE allows direct elimination of plasma cholesterol in the feces directly via the intestine. Until now, only indirect evidence suggests that TICE is also active in humans, the goal of this proof of concept study is to provide the first proof of its existence in humans by using stable isotopes in patients with bile duct diversion.

NCT ID: NCT01906827 Recruiting - Arrhythmia Clinical Trials

P-wave Duration and Dispersion in Intrahepatic Cholestasis of Pregnancy

Start date: July 2013
Phase: N/A
Study type: Observational

The bile acids has been demonstrated to cause arrhythmia and abnormal calcium dynamics in cultured neonatal rat cardiomyocytes. Bile acids may alter maternal cardiomyocyte function like fetus.Increased P-wave duration and P-wave dispersion have been reported in various clinical settings. The investigators hypothesized that PWD and p wave duration may affect in pregnancy with ICP.

NCT ID: NCT01898832 Recruiting - Clinical trials for Intrahepatic Cholestasis of Pregnancy

Il-17 Levels in Intrahepatic Cholestasis of Pregnancy

Start date: July 2013
Phase: N/A
Study type: Observational [Patient Registry]

The aim of this study is to investigate maternal and fetal serum IL-17 levels in pregnant women with intrahepatic cholestasis of pregnancy and to find out if Th-17 cells have a role in progress of intrahepatic cholestasis of pregnancy.

NCT ID: NCT01755013 Recruiting - Cholangiocarcinoma Clinical Trials

Photodynamic Therapy (PDT) for Palliation of Cholangiocarcinoma

Start date: February 2012
Phase: Phase 2/Phase 3
Study type: Interventional

Successful palliation of biliary obstruction is the main goal for reducing morbidity and mortality in patients with biliary disease and biliary obstruction related to cholangiocarcinoma. Surgical intervention for the sale is unfortunately complicated by a 30-day postoperative mortality rate of between 7 and 24%. Moreover, because of recovery time the quality of life following surgery is only improved in a minority. At present endoscopic insertion of a plastic or metal stent is the method of choice to relieve obstructive jaundice without the high morbidity and mortality associated with surgery. But this relief is unfortunately temporary since stents tend to become obstructed and the fact that effective biliary drainage in the proximal lesion is challenging. Photodynamic Therapy (PDT) is a new therapeutic approach that specifically targets neoplastic cells. This therapy involves the intravenous administration of a photosensitizing agent followed by activation of the agent by illumination with non-thermal light of a specific wavelength, resulting in cell death from direct cytotoxicity and ischemic necrosis. A randomized controlled trial study by Ortner et all confirmed the significant advantage of PDT with regard to relief of jaundice, quality of life, and survival. In photodynamic therapy (PDT) the uniform distribution of externally applied light is desirable but often difficult to achieve. An optical fiber tip producing cylindrical or lateral light emission can facilitate the application of laser energy by direct implantation of the tip into solid tumors. However, currently used FDA approved glass diffusers used in standard of care PDT might break in the bile ducts causing injury since they are not meant to be used within bile ducts through an endoscope or choledochoscope. Hence, there is a need to evaluate and introduce more efficient and safe non-glass cylindrical optic fiber diffuser for photo dynamic therapy in the bile ducts. Recent studies have shown that the Pioneer plastic optic diffuser is safe and effective in photodynamic therapy, it can be also used via a choledochoscope. We aim to add to the clinical evidence by conducting an open label observational study trial using this fiber optic diffuser during photo dynamic therapy in the bile ducts.